Johnson & Johnson Family of Companies
NEWS
It was a busy week for clinical trial announcements and news. Here’s a look.
South Africa recently announced it was halting distribution of the AstraZeneca-University of Oxford COVID-19 vaccine after data suggested it “provides minimal protection” against mild disease from the South African variant.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
Johnson & Johnson’s Janssen Biotech submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) for its single-dose COVID-19 vaccine.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
Overall, against moderate-severe COVID-19 infection, the vaccine was 72% effective 28 days after vaccination in the U.S., 66% in hard-hit Latin America, and bottomed out at 57% in South Africa.
It was a busy week for clinical trial news. Read on for more information.
J&J indicated it will soon release Phase III data and could file for Emergency Use Authorization with the U.S. Food and Drug Administration by the end of the month.
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca for the last few months has been on their COVID-19 vaccine efforts.
JOBS
IN THE PRESS